Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,206.40
(
0.01%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.71
(
-0.49%
)
Bitcoin
77,793.20
(
-0.62%
)
News Focus
News Focus
Post# of 822657
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

GoodGuyBill

Send PM Follow Ignore
Followers 67
Posts 6013
Boards Moderated 0
Alias Born 09/16/2013

GoodGuyBill

Re: hope4patients post# 222730

Monday, 04/15/2019 3:51:49 PM

Monday, April 15, 2019 3:51:49 PM

Post# of 822657
Shouldn't this be 2.1%?

Only 21% of patients had grade 3 or 4 adverse events. The results of this Phase III clinical trial show promising feasibility of integrating DCV into standard therapy and suggests a survival benefit [214]."

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News